Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-09-04
GPRC5D-Targeted Therapies Active Trials in China
As of 2026-09-04, there are 14 active clinical trials investigating GPRC5D-Targeted Therapies for multiple myeloma across 28 provinces and 318 study centers in China. GPRC5D is an orphan receptor expressed on malignant plasma cells independently of BCMA. Because the two do not share an expression pathway, GPRC5D-directed agents are frequently explored for patients who relapse after BCMA-directed therapy or lose target antigen expression.
Active Trials
14
Provinces
28
Centers
318
Active Studies (14)
Population synthesized by CMDNShowing 7 published English records of 14 registry trials.
Phase IIICTR20262221
RecruitingA Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Target Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Shanghai Fourth People's Hospital 等 222 家中心
Phase ITM20260016
RecruitingA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Target Population: Relapsed/refractory
Target: In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
Study Sites: Cancer Hospital, Chinese Academy of Medical Sciences
Early Exploratory Clinical StudyNCT07622862
RecruitingAn Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Allogeneic universal CAR-T targeting BCMA/GPRC5D
Study Sites: Zhongshan Hospital, Xiamen University
Phase I/IICTR20243384
RecruitingA Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Trispecific antibody targeting GPRC5D, BCMA, and CD3
Study Sites: Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University、The Affiliated Hospital of Xuzhou Medical University 等 23 家中心
Phase Ib/IICTR20232814
RecruitingAn Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Target Population: Relapsed/refractory
Target: GPRC5D-targeted CAR-T
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 8 家中心
Phase IICTR20261752
RecruitingA Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Target Population: Multiple myeloma
Target: Trispecific antibody targeting BCMA, CD3, and GPRC5D
Study Sites: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Heze Municipal Hospital 等 39 家中心
Phase IIICTR20262035
RecruitingA Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: GPRC5D/BCMA/CD3 trispecific antibody
Study Sites: Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The Affiliated Hospital of Xuzhou Medical University 等 45 家中心